In this content, it is worth mentioning that navitoclax, a Bcl-2/Bcl-xL inhibitor, is under evaluation in phase I/II trial study in combination with dabrafenib and trametinib in patients with BRAF-mutant solid tumors, including melanoma (ClinicalTrials.gov Identifier: NCT01989585), and in triple negative breast cancer patients in combination with the PARP inhibitor olaparib in a phase I study (ClinicalTrials.gov Identifier: NCT05358639), while the Bcl-2 inhibitor, TQB3909, is under evaluation in phase Ib/II study in breast cancer patients (ClinicalTrials.gov Identifier: NCT05775575). Here, BRAF is linked to triple-negative breast carcinoma.